Articles tagged with Drug Resistance
A cheap and widely used drug lansoprazole may have useful activity against Mycobacterium tuberculosis, the bacteria that cause tuberculosis. The study found people taking lansoprazole were a third less likely to develop TB than those taking similar drugs.
Anita Mattson's research focuses on naturally occurring molecules known as dimeric chromanones, which have high biological activity and may become powerful dual-action treatments for drug-resistant cancers. Her goal is to develop a new class of catalysts using silanediols to control the synthesis of these compounds.
Research from MD Anderson Cancer Center suggests that chronic stress hormones can promote resistance to EGFR inhibitors in lung cancer patients. However, using beta blockers may slow or prevent this resistance, according to the study's findings.
A new study reveals that non-small cell lung cancers are driven by multiple genetic changes, including alterations in TP53 and other pathways. The findings suggest that combination therapies targeting these mutations may improve treatment outcomes and prevent drug resistance.
A new treatment reduced disease burden in patients with skin-predominant dermatomyositis, improving patient-reported quality of life and symptom assessments. The treatment, anabasum, was well-tolerated with mild side effects.
Researchers analyzed over 600 drug and breast cancer cell pairings, revealing significant changes in gene expression without affecting cell growth or survival. The study identified potential synergistic combinations of drugs, including trametinib and alpelisib, to overcome adaptive resistance mechanisms.
Researchers have developed a CRISPR-Cas9-based gene drive platform to create diploid strains of C. albicans, allowing for the efficient deletion of genes involved in drug resistance and biofilm formation. The approach identified synergistic combinations of genes that contribute to these traits.
Scientists have found that a rare genetic disease known as NGLY1 deficiency could hold the key to understanding resistance to cancer drugs. Dampening this enzyme may allow proteasome inhibitors to continue killing cancer cells, providing hope for new treatments.
Researchers at the University of Wisconsin-Madison have successfully characterized a highly pathogenic avian virus that is both lethal and transmissible in ferrets. The study suggests that this virus strain could become a potential public health threat if it undergoes further mutations, making it resistant to existing treatments.
Researchers found that epigenetic regulation can increase Wnt signaling to promote cell proliferation, leading to resistance to cetuximab. Blocking Wnt signaling may restore responsiveness to the drug in cultured colon cancer cells and mice tumors.
A laboratory-based study discovered that an alcohol aversion drug can reverse chemotherapy resistance in non-small cell lung cancer. The researchers found that the drug, Disulfiram, inhibited ALDH activity, reducing tumour cell growth and killing lung cancer stem cells.
Researchers at Lund University have successfully isolated and studied the plant compound damsin, which inhibits the growth and spread of cancer stem cells. The study's findings suggest that damsin and its synthetic analogue ambrosin may contribute to the development of new drugs against cancer stem cells.
A specific mutation in the DNA of the fungal pathogen Cryptococcus deuterogattii increases its mutation rate, allowing it to rapidly develop resistance to antifungal drugs like FK506 and rapamycin. This hypermutator trait is likely widespread among pathogenic fungi.
Researchers found that flu viruses can evolve rapidly due to their ability to hijack host chaperone proteins, which help mutated viral proteins fold and function. Targeting these proteins could delay viral evolution and decelerate escape from existing drugs and vaccines.
Researchers at RUDN University discovered a redox-dependent mechanism that enables ovarian and breast cancer cells to resist chemotherapy. The mechanism involves the expression of genes encoding thioredoxin and peroxiredoxin, which play a crucial role in the antioxidant defense system.
Researchers aim to identify parasite genes underlying resistance, monitor spread, and design treatment strategies. They will use innovative genetic crosses in a 'humanized' mouse strain to better understand drug resistance evolution.
Researchers at the University of Pennsylvania have identified a new target for cancer therapies by blocking an enzyme crucial to tumor growth and a process that causes resistance to current treatments. A new drug called DQ661 successfully inhibits tumor growth in mice with melanoma, pancreatic, and colorectal cancers.
Researchers at Tulane University have developed a new drug, AQ-13, effective against non-severe cases of malaria. The clinical trial results match the effectiveness of widely used treatment regimens and hold promise for combating drug-resistant Plasmodium falciparum strains.
A phase III clinical trial found that osimertinib improves progression-free survival and median duration of response by 50-100% compared to standard first line therapy for patients with EGFR mutated non-small-cell lung cancer. The benefit was consistent across all subgroups, including those with and without brain metastases.
Researchers at the University of Southern Denmark have discovered a new strategy to overcome resistance in lung cancer, which often leads to treatment failure. By combining an EGFR tyrosine kinase inhibitor with an AKT inhibitor, tumor growth can be arrested, potentially improving patient survival.
A new class of compounds, hexahydroquinolines (HHQs), shows promise in preventing Plasmodium falciparum parasite transmission from infected hosts to mosquitoes. HHQs also enhance the effectiveness of existing antimalarial treatments, making it harder for drug-resistant parasites to emerge.
Researchers propose a novel antibacterial combination to combat drug-resistant tuberculosis, with potent sterilizing activity against highly resistant strains. The study suggests that pairing ceftazidime and avibactam could be an effective treatment option for patients with extensively drug-resistant tuberculosis.
A new microfluidic cell culture device allows researchers to study the development of drug resistance in cancer cells in real-time. The system, developed by Princeton University and Johns Hopkins Medical Institute, provides a tool for preclinical cancer drug development and screening.
The PATHWAY-2 study finds that salt retention is the main cause of drug-resistant hypertension and that older diuretic medications are the most effective treatment. The research discovered that spironolactone and amiloride work equally well in lowering blood pressure, offering new alternatives for patients with resistant hypertension.
Researchers are developing a new class of biological therapeutics that can coevolve with viruses, potentially eliminating or blunting resistance. By leveraging natural phenomena like defective interference, they aim to create therapeutic interfering particles that can reduce disease severity and transmission.
Engineers at MIT found that organelles like mitochondria and lysosomes encounter different types of resistance in cytoplasm based on size and speed. The researchers developed a phase diagram to describe the material properties of cytoplasm from an organelle's perspective, which may aid in pharmaceutical designs.
Researchers have confirmed that a Dutch isolate of the parasite Cystoisospora suis is resistant to toltrazuril, a common treatment used in Europe. This development highlights the need for increased hygiene measures and monitoring of resistance to prevent the spread of resistant parasites.
A recent study predicts cancer drug resistance and sensitivity by analyzing genomic alterations and their interactions. Researchers used The Cancer Genome Atlas dataset to create a map of oncogenic dependencies, revealing that certain genetic changes can make tumors resistant to some drugs while making them sensitive to others.
Researchers at Mayo Clinic have identified a link between SPOP gene mutations and treatment resistance in prostate cancer. The discovery suggests ways to improve therapy by using these mutations as biomarkers. This breakthrough could lead to more effective treatments for this common and deadly form of cancer.
A new hybrid biomaterial delivers a chemotherapeutic agent and RNA interfering technology to silence drug resistance, resulting in substantial decrease in cancer cell viability. The material's ease of modification allows for swapping out components to suit specific cell lines and drugs.
A study published in Multiple Sclerosis Journal shows that resistance training can protect the brain and delay disease progression in people with multiple sclerosis. The research, conducted over six months, found that those who engaged in resistance training had less brain shrinkage and even small brain areas began to grow.
Scientists at James Cook University warn that concurrent training can impair endurance development if recovery is not accounted for. They propose a new approach to mitigate resistance training-induced fatigue, which can affect athletes' performance several days after a single session.
A Massachusetts General Hospital research team found that anti-angiogenic drugs induce a microenvironment that suppresses immune systems actions, allowing tumors to grow. Developing a potential strategy to overcome this mechanism, the researchers identified CX3CL1 as an attractive target for immunotherapy.
A national survey of rural physicians found significant barriers to prescribing buprenorphine for opioid use disorder, including time constraints and lack of mental health support services. The study calls for tailored strategies to address these barriers and support physicians in providing Buprenorphine Maintenance Treatment.
Currently available drugs may be used alone or in combination to treat infectious diseases, addressing a pressing need due to slow development of new therapies. Non-profit entities and private industry collaboration is crucial for discovering novel interventions to combat drug-resistant pathogens.
New research from the University of Pennsylvania School of Medicine finds that lenvatinib improves overall survival rates in older thyroid cancer patients who are resistant to standard radioiodine treatment. The drug is well-tolerated and has a significant impact on patient outcomes.
Women are at greater risk of cardiovascular disease due to longer lifespan and differences in drug absorption, distribution, and metabolism compared to men. The European Society of Cardiology recommends sex-specific guidelines for cardiovascular drugs to minimize adverse reactions.
Researchers at LSTM and partners have developed a molecule, E209, effective against parasites with artemisinin resistance. The fully synthetic molecule is designed to be fast-acting and slowly eliminated, offering hope as a single-dose cure.
Research finds that tulip bulbs from the Netherlands are carrying a fungal pathogen resistant to key antifungal therapy, Voriconazole. The discovery raises concerns for immunocompromised patients and highlights the need for vigilance in preventing the spread of resistance.
The researchers discovered that major biological signalling circuits can be made to resonate when driven at their resonant frequency, allowing for the control of cell signalling pathways. This method has potential relevance in the treatment of diseases and could guide the discovery of new therapeutic approaches.
The FDA approves brigatinib as a second-line therapy for ALK-positive non-small cell lung cancer, demonstrating a 54% response rate and 12.9-month progression-free survival. Brigatinib's longer control duration compared to other next-generation ALK inhibitors suggests its broader spectrum of coverage against resistance mechanisms.
Researchers discovered a key molecule VCP linked to Human Cytomegalovirus replication, which can be blocked by chemicals to stop the virus from multiplying. This approach could lead to more powerful therapies and reduce the risk of resistance.
The Critical Path Institute and Translational Genomics Research Institute will sequence at least 12,000 tuberculosis bacteria isolates from around the world to better understand drug resistance. The partnership aims to develop personalized medicine options for patients with drug-resistant TB.
Researchers have identified a genetic signature associated with resistance in triple negative breast cancer, which can be reversed after a period of treatment cessation. This discovery may lead to personalized chemotherapy strategies and improved treatment outcomes.
Researchers have proven that understanding and predicting tumor resistance can lead to additional treatment options in the clinical setting. By studying non-small cell lung cancer cells, the team found that some drugs are more susceptible to other drugs, even when resistant to a single drug.
Dr. Katerina A. Politi has made significant contributions to the understanding and treatment of EGFR mutant lung cancer. Her research has led to a paradigm-shift in the diagnosis and treatment of lung cancer, including the early adoption of molecular profiling.
A new and inexpensive treatment option for drug-resistant malaria has been developed using plant therapy made from dried leaves of the Artemisia annua plant. The treatment, known as DLA, was tested on 18 critically ill patients in a Congo clinic and showed a 100% recovery rate, including a five-year-old child who had lapsed into a coma.
Researchers identify detailed structure of protein complex used by bacteria to detect environmental changes and adapt to them. This discovery sheds light on how bacteria develop resistance to antibiotics.
A combination of a PARP inhibitor and a kinase inhibitor showed significant tumor shrinkage in 36% of patients with platinum-resistant ovarian cancer, a surprising improvement over solo PARP inhibitor treatment. The treatment was well-tolerated, with four patients discontinuing due to toxicity.
Scientists at Liverpool School of Tropical Medicine have created a new way to screen potential treatments for Tuberculosis (TB), which may reduce treatment duration from six months to weeks.
Researchers at Mass General Hospital identified novel resistance mechanisms in patients with liver tumors receiving FGFR inhibitor treatment. The study found that different mutations within individual patients and across multiple samples could confer resistance, highlighting the need for more effective treatments.
Trichomonosis is a common infectious cause of large bowel diarrhea in cats, characterized by 'cow pie' consistency and mucus/blood in faeces. The infection is caused by the protozoan Tritrichomonas foetus, which can be transmitted from cat to cat via the faecal-oral route.
Scientists have found that two immune system molecules, interleukin 1 beta (IL1β) and tumor necrosis factor alpha (TNFα), may drive drug resistance in estrogen-driven breast cancers by modifying the shape of the estrogen receptor. This finding could lead to novel therapeutic approaches.
Researchers identified a secondary pathway to reactivate EthA enzyme in resistant TB strains, boosting treatment efficacy. The combination of SMARt-420 and ethionamide effectively treated resistant TB strains, reducing bacterial load in mouse lungs.
Researchers at Cardiff University have devised a new way of creating the leading anti-malarial drug artemisinin, which could reduce market fluctuations in the supply chain and help study resistance to the drug. The new method bypasses several key steps in the production process, achieving the desired outcome in just four steps.
Researchers have created a detailed atomic map of the frontline antimalarial drug mefloquine, showing how its structure could be tweaked to increase effectiveness. The study aims to create a more targeted and safer treatment by redesigning the drug's molecular machinery.
Researchers have created a precise atomic map of the frontline antimalarial drug mefloquine, showing how its structure could be changed to make it more effective. The study provides a route to develop new treatments with fewer resources and potentially reduced side effects.
Researchers at Mayo Clinic have identified a specific protein implicated in drug resistance, as well as a possible therapeutic tool. By engineering a peptide that blocks the activity of another protein ERK, the team found that it can prevent chemotherapy resistance and tumor growth.
Research reveals that expression levels of ABCB1 and ABCG2 transporters significantly affect cell resistance to Dasatinib. Lower transporter expression levels mediate lower resistance, implying a potential breakthrough for targeted cancer treatment.
Research reveals that only one in five patients with resistant hypertension are taking all their prescribed medications, while 20% are not taking any. The study found that adherence to medication greatly affects the ability to assess the value of another treatment, and patients can take steps to prevent high blood pressure from remaini...